StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma r&d expenses

Research and development expenses are spending on new products and technology.

UroGen Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $61.26M, down 5.8% year over year. For fiscal 2025 it was $67.11M, up 17.4% from the year before. The highest annual figure on record is $67.11M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.11M+17.4%
FY2024Dec 31, 2024$57.15M+25.3%
FY2023Dec 31, 2023$45.61M-13.8%
FY2022Dec 31, 2022$52.91M+11.0%
FY2021Dec 31, 2021$47.64M+0.7%
FY2020Dec 31, 2020$47.31M-4.0%
FY2019Dec 31, 2019$49.30M+33.5%
FY2018Dec 31, 2018$36.93M+97.5%
FY2017Dec 31, 2017$18.70M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$17.34M-8.3%
Q1 FY2026Mar 31, 2026$15.60M-21.5%
Q4 FY2025Dec 31, 2025$14.31M-3.9%
Q3 FY2025Sep 30, 2025$14.01M+23.4%
Q2 FY2025Jun 30, 2025$18.91M+22.8%
Q1 FY2025Mar 31, 2025$19.87M+28.2%
Q4 FY2024Dec 31, 2024$14.89M+31.8%
Q3 FY2024Sep 30, 2024$11.36M+11.0%
Q2 FY2024Jun 30, 2024$15.40M+33.0%
Q1 FY2024Mar 31, 2024$15.49M+24.0%
Q4 FY2023Dec 31, 2023$11.30M-21.9%
Q3 FY2023Sep 30, 2023$10.23M-21.9%
Q2 FY2023Jun 30, 2023$11.58M-8.4%
Q1 FY2023Mar 31, 2023$12.50M-1.6%
Q4 FY2022Dec 31, 2022$14.48M+10.7%
Q3 FY2022Sep 30, 2022$13.09M+9.8%
Q2 FY2022Jun 30, 2022$12.64M+4.3%
Q1 FY2022Mar 31, 2022$12.70M+20.8%
Q4 FY2021Dec 31, 2021$13.08M+5.5%
Q3 FY2021Sep 30, 2021$11.92M+16.8%
Q2 FY2021Jun 30, 2021$12.12M+49.6%
Q1 FY2021Mar 31, 2021$10.51M-36.6%
Q4 FY2020Dec 31, 2020$12.41M-38.3%
Q3 FY2020Sep 30, 2020$10.21M+7.7%
Q2 FY2020Jun 30, 2020$8.11M-18.9%
Q1 FY2020Mar 31, 2020$16.59M+70.6%
Q4 FY2019Dec 31, 2019$20.09M+75.3%
Q3 FY2019Sep 30, 2019$9.48M-1.0%
Q2 FY2019Jun 30, 2019$10.00M+20.8%
Q1 FY2019Mar 31, 2019$9.73M+27.6%
Q4 FY2018Dec 31, 2018$11.47M+69.6%
Q3 FY2018Sep 30, 2018$9.57M+70.3%
Q2 FY2018Jun 30, 2018$8.27M+126.6%
Q1 FY2018Mar 31, 2018$7.62M+186.1%
Q4 FY2017Dec 31, 2017$6.76M–
Q3 FY2017Sep 30, 2017$5.62M–
Q2 FY2017Jun 30, 2017$3.65M–
Q1 FY2017Mar 31, 2017$2.66M–

More UroGen Pharma figures

See a number that looks wrong?